CJC-1295 vs Sermorelin: Half-Life, Pulsatility and How to Choose

The core distinction is duration: sermorelin is essentially the natural growth hormone-releasing signal itself and clears quickly, while CJC-1295 is that signal re-engineered to last — in its DAC form latching onto your own albumin and nudging the pituitary for days rather than minutes.

The short version. Neither is growth hormone and neither replaces it; both ask the pituitary to release more of its own. Sermorelin is GHRH(1-29), the shortest active piece of the natural hormone, and its effect is brief and sharply pulsed. CJC-1295 comes in two forms — without DAC it behaves much like sermorelin, while with DAC it bonds permanently to albumin and its half-life stretches into days. That drives injection frequency, what your IGF-1 does, and where to start.

Why Working Upstream Is the Appealing Part

Your pituitary already knows how to make growth hormone, releasing it in bursts governed by growth hormone-releasing hormone pushing and somatostatin restraining. A secretagogue works at the top of that system rather than bypassing it: sermorelin and CJC-1295 are both GHRH analogues, binding the GHRH receptor on the somatotroph cells of the anterior pituitary and asking those cells to secrete. That differs meaningfully from introducing growth hormone from outside, because the restraint mechanisms stay in circuit — somatostatin tone and IGF-1 feedback still apply, and the pituitary can only release what it can.

Which means your own pituitary reserve becomes the ceiling. As the researchers who measured CJC-1295's effect on human growth hormone pulses put it, long-acting GHRH preparations may have clinical utility in patients with intact pituitary secretory capability (Ionescu and Frohman, J Clin Endocrinol Metab, 2006, DOI). Establishing that is part of the consultation.

Sermorelin: The Signal Itself, Briefly

Human GHRH is 44 amino acids long, but essentially all its activity lives in the first 29. Sermorelin is that fragment — GHRH(1-29) amide. It is not a mimic of GHRH so much as the working part of it, which is why it tracks the natural signal so closely. Including the brevity. Researchers developing longer-acting versions state the obstacle plainly: therapeutic use of GHRH to enhance growth hormone secretion is limited by its short duration of action (Teichman et al., J Clin Endocrinol Metab, 2005, DOI). Part of the reason is enzymatic — GHRH is a substrate for dipeptidylpeptidase-IV, and resistance to that enzyme was deliberately engineered into the longer-acting analogues (Jetté et al., Endocrinology, 2005, DOI).

In a five-month randomised, placebo-controlled trial, nine men and ten women aged 55 to 71 self-injected a GHRH(1-29) analogue nightly at 9pm. Within ten minutes it induced an acute release of growth hormone, which lasted for two hours — and that effect was sustained across the whole study, meaning the pituitary did not stop responding (Khorram et al., J Clin Endocrinol Metab, 1997, DOI). Ten minutes on, two hours off: that is the shape of sermorelin, covered on its own terms on our sermorelin page.

CJC-1295: Two Molecules Sharing One Name

CJC-1295 with DAC is what the published research is about: a tetrasubstituted form of human GHRH(1-29) carrying a maleimide group at the C-terminus, the Drug Affinity Complex. That group is chemically reactive toward one target — the free thiol on cysteine-34 of serum albumin. After injection the peptide bonds covalently to circulating albumin, becoming a peptide riding a protein with a multi-week lifespan, protected from the enzymes that would otherwise clear it (Jetté et al., 2005, DOI). A later analytical paper describes the same mechanism and notes these conjugates are capable of stimulating growth hormone production for more than six days in humans after a single administration (Timms et al., Drug Test Anal, 2019, DOI).

CJC-1295 without DAC is the same backbone with stabilising substitutions but no albumin-binding group, often sold as modified GRF(1-29). No anchor, no extended circulation — so it behaves much more like sermorelin: fast on, fast off. That is mechanism, clearly labelled: every human trial cited here studied the DAC version, and we found no published human trials of the no-DAC form of comparable quality.

Half-Life: The Number That Changes Everything

Two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61 established the pharmacokinetics of CJC-1295 with DAC. A single subcutaneous injection produced dose-dependent increases in mean plasma growth hormone of two- to ten-fold lasting six days or more, and in IGF-1 of 1.5- to three-fold lasting nine to eleven days. The estimated half-life was 5.8 to 8.1 days, and after multiple doses IGF-1 stayed above baseline for up to 28 days, with evidence of a cumulative effect (Teichman et al., 2005, DOI).

Set that next to sermorelin's two-hour window (Khorram et al., 1997, DOI) and the difference is not incremental: roughly two hours versus roughly a week, from two molecules built on the same 29 amino acids.

Pulsatility Versus Sustained Elevation

The obvious worry about a week-long GHRH signal is that it flattens the natural rhythm into a plateau. This was tested directly: healthy men aged 20 to 40 underwent overnight 12-hour sampling every 20 minutes, before and one week after a single CJC-1295 injection. Secretion increased with pulsatility preserved — pulse frequency and magnitude were unaltered. What changed was the floor: trough growth hormone rose 7.5-fold, driving a 46 percent rise in mean growth hormone and a 45 percent rise in IGF-1 (Ionescu and Frohman, 2006, DOI). The pulses still happen; they now sit on a raised baseline.

Why does that matter? Because the pattern of delivery is itself a biological signal, not a cosmetic detail. Pulsatile, but not continuous, growth hormone exposure activates the liver transcription factor STAT5b, and mice lacking STAT5b lose a set of growth-rate and liver gene expression responses despite not being growth hormone deficient (Udy et al., Proc Natl Acad Sci USA, 1997, DOI); a review of that field concludes the temporal pattern of release, not merely the amount, determines large parts of hepatic gene transcription (Waxman and O'Connor, Mol Endocrinol, 2006, DOI). Rodent-dominated mechanism — but it is why clinicians take pattern seriously, and why preserved pulses matters.

Protocols and Dosing Frequency

We do not publish doses or injection schedules, and we would be sceptical of a clinic that did. Dosing is individualised and set by a prescribing clinician. The literature establishes only the general shape.

Short-acting peptides are dosed frequently, and at night. Trials used nightly bedtime injections for 16 weeks (Khorram et al., 1997, DOI), or twice-daily injections, which in men averaging 68 years old restored mean 24-hour growth hormone and IGF-1 to levels not significantly different from a young comparison group (Corpas et al., J Clin Endocrinol Metab, 1992, DOI). Bedtime timing stacks the induced pulse onto the largest nocturnal secretory episode.

Long-acting CJC-1295 with DAC is dosed on a scale of days to weeks. Its human trials used single, weekly or biweekly dosing (Teichman et al., 2005, DOI). Interval still matters: in mice lacking their own GHRH gene, once-daily CJC-1295 maintained normal body composition and growth while the same dose every 48 or 72 hours was less effective (Alba et al., Am J Physiol Endocrinol Metab, 2006, DOI) — an animal study, but it shows a long half-life does not make frequency irrelevant. For many people the honest deciding factor is adherence: a nightly injection is a nightly decision, a hundred times a quarter.

What Results Realistically Look Like

Biochemistry moves first. In the 16-week GHRH(1-29) trial, nocturnal growth hormone rose significantly in both sexes and within two weeks serum IGF-1 and IGFBP-3 had risen significantly (Khorram et al., 1997, DOI); with CJC-1295, IGF-1 rose after a single dose (Teichman et al., 2005, DOI).

Body composition moves slower, and modestly. That same trial found significantly increased skin thickness in both sexes but increased lean body mass in men only, with no other significant change in body composition or bone mineral density; insulin sensitivity, general well-being and libido likewise improved in men but not women. The authors concluded the anabolic effects favoured men more than women (Khorram et al., 1997, DOI). We report that because it is in the data, and omitting it would set up half our patients for disappointment.

Broader evidence comes from the longer-acting analogue tesamorelin: in 412 adults, 26 weeks of daily treatment reduced visceral adipose tissue by 15.2 percent while it rose 5.0 percent on placebo (Falutz et al., N Engl J Med, 2007, DOI). A systematic review pooling ten randomised placebo-controlled trials across 1,511 patients found growth hormone axis treatments decreased visceral fat and increased lean body mass by a weighted mean difference of 1.31 kg (Sivakumar et al., HIV Med, 2011, DOI). Those were specific clinical populations, so they show what the mechanism can do rather than predicting your result. A kilogram of lean mass is real and modest — not a physique transformation, and anyone promising you one is not reading the same papers.

Sleep and recovery are genuinely interesting and genuinely unsettled. The link between deep sleep and growth hormone is not in doubt: there is a linear relationship between the amount of slow-wave sleep and concomitant growth hormone secretion, and with ageing both decline exponentially and with the same chronology (Van Cauter and Copinschi, Growth Horm IGF Res, 2000, DOI). In 48 adults studied across recovery sleep after 40 hours of deprivation, GHRH increased non-REM sleep and decreased wakefulness more than placebo (Schüssler et al., Am J Physiol Endocrinol Metab, 2006, DOI) — though the same paper notes a sexual dimorphism in ordinary sleep, where GHRH impaired sleep in women, and the 16-week nightly trial found sleep quality unaffected in both sexes (Khorram et al., 1997, DOI). Better sleep is a common patient report; the published picture is mixed, and we would rather say so than sell it.

The timeline, honestly. Labs shift in weeks; body composition, in every controlled trial cited here, was measured at 16 to 26 weeks. Plan in months.

Monitoring and Labs

IGF-1 is the workhorse measurement: growth hormone itself is pulsatile, so a single random draw tells you almost nothing, whereas IGF-1 integrates the signal over days. Every trial above used it as the primary readout. The goal is not the highest number achievable. In a 20-week randomised, double-blind, placebo-controlled trial of 152 adults aged 55 to 87 on a daily GHRH analogue at bedtime, IGF-1 rose 117 percent and the authors specifically noted it remained within the physiological range, alongside a favourable effect on cognition and a 7.4 percent fall in body fat (Baker et al., Arch Neurol, 2012, DOI). A band appropriate for your age and sex is the target.

Glucose metabolism is tracked alongside it, because this axis and insulin sensitivity interact in both directions. In the 26-week tesamorelin trial, no significant differences were observed in glycaemic measures (Falutz et al., 2007, DOI); in the 20-week trial, fasting insulin rose 35 percent within the normal range in the mild cognitive impairment subgroup but not in the healthy adults (Baker et al., 2012, DOI). Different populations, different answers — which is why it is measured in you rather than assumed. Baseline labs, a recheck once the protocol has registered, then periodic monitoring.

Safety

In the CJC-1295 pharmacokinetic trials, no serious adverse reactions were reported and the authors described the compound as safe and relatively well tolerated, particularly at the middle doses (Teichman et al., 2005, DOI). In the 412-patient tesamorelin trial, adverse events did not differ significantly between treatment and placebo, though more treated patients withdrew because of one (Falutz et al., 2007, DOI). The systematic review found these drugs well tolerated, with statistically significant side effects including arthralgias and oedema (Sivakumar et al., 2011, DOI) — joint aching and fluid retention, usually dose-related.

These are prescription medications, prescribed and supervised here by a clinician after your history is taken, your labs reviewed and contraindications excluded. There are people for whom stimulating this axis is not appropriate, and identifying them is part of the consultation — not something a website can do.

How the Choice Is Made at Arbour Longevity

Not by picking a favourite molecule. Your baseline comes first: IGF-1, metabolic markers and a full history, because the upstream approach depends on intact pituitary secretory capability (Ionescu and Frohman, 2006, DOI). What you are trying to change matters next — sleep, body composition and general vitality have different timelines. How much control you want over the signal is the underrated one: a short-acting peptide is easy to titrate and easy to stop, while a week-long half-life with a cumulative IGF-1 effect (Teichman et al., 2005, DOI) is less nimble in both directions — which is why responsiveness often beats convenience for a first course. And whether you will actually do it: nightly versus weekly is not trivial over six months.

If you are weighing these against other secretagogues, our comparison of tesamorelin vs sermorelin vs ipamorelin covers that ground, including how ghrelin-receptor peptides differ from the GHRH analogues here. Our peptide therapy and peptide pages show how these fit a longer plan.

Frequently Asked Questions

Is CJC-1295 stronger than sermorelin?

Longer-lasting rather than stronger — both bind the same receptor. CJC-1295 with DAC has an estimated half-life of 5.8 to 8.1 days and raises IGF-1 for nine to eleven days after one injection (Teichman et al., 2005, DOI); a GHRH(1-29) injection produced a release lasting about two hours (Khorram et al., 1997, DOI). Sustained exposure gives a larger integrated effect, not a stronger receptor signal.

Does CJC-1295 ruin my natural growth hormone rhythm?

The direct study of this found it did not: one week after a single injection, overnight sampling every 20 minutes showed pulse frequency and magnitude unchanged, with the increase coming from a 7.5-fold rise in trough levels (Ionescu and Frohman, 2006, DOI). Pulses preserved, floor raised.

What is the difference between CJC-1295 with DAC and without DAC?

DAC is a maleimide group that bonds covalently to cysteine-34 on your own serum albumin after injection, producing the extended half-life (Jetté et al., 2005, DOI; Timms et al., 2019, DOI). Without it there is no anchor, so the peptide acts and clears quickly. The no-DAC form has far less published human data, and we say so rather than borrowing the DAC evidence for it.

Will this actually change my body composition?

Modestly, and less predictably than the marketing suggests. Sixteen weeks of nightly GHRH(1-29) increased lean body mass in men but not women (Khorram et al., 1997, DOI), and pooled across ten randomised placebo-controlled trials, growth hormone axis treatments increased lean mass by a weighted mean of 1.31 kg and reduced visceral fat (Sivakumar et al., 2011, DOI). Real and measurable, not dramatic, and dependent on training and nutrition doing their part.

What gets monitored while I am on it?

IGF-1 primarily, because growth hormone itself is too pulsatile for a single draw to mean much, plus glucose and insulin. The aim is a level appropriate for your age and sex rather than the highest achievable — in that 152-adult trial a 117 percent IGF-1 increase still sat within the physiological range (Baker et al., 2012, DOI).

Growth Hormone Peptide Consultations in Ann Arbor

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner. We are at 2217 Packard St #15, in the Eastover Professional Center, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, closed Tuesday and Wednesday. Parking is free and directly outside — no meters, no structure. Suite 15 is down a flight of stairs, so if stairs are difficult for you, please call (734) 436-3357 before visiting.

Call (734) 436-3357 or book your first visit. The first visit is $35, applied toward your treatment plan. Cash pay, HSA and FSA accepted.

Clinical information on this page is drawn from articles retrieved from PubMed and is provided for education. It is not medical advice, not a diagnosis, and not a promise of any individual result.